Phase II Trial of TAS-102 in Colorectal Cancer Patients With Circulating Tumor DNA-Defined Minimal Residual Disease After Adjuvant Therapy: INTERCEPT-TT A multiplex QIF assay was optimized on tissue ...
Multiplex assay tech detects multi-biomolecules in single samples on xMAP/CBA, with high sensitivity and consistency ...
“These results reinforce the data previously presented at ASCO GI, where our tissue-free Latitude MRD assay demonstrated high overall concordance to Signatera™ as well as strong standalone clinical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results